Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
National Cancer Institute (NCI)
Sotio Biotech Inc.
Amgen
Inspirna, Inc.
Carisma Therapeutics Inc
University of Florida
Fate Therapeutics
Xencor, Inc.
Gossamer Bio Inc.
Merck Sharp & Dohme LLC